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Delayed pressure urticaria is a physical urticaria
where erythematous, often painful swellings occur at
sites of sustained pressure on the skin, after a delay
of several hours. If sought, it is present in up to 40%
of patients with ordinary chronic ``idiopathic urti-
caria'' to a varying degree. Compared with other
urticarias, the pressure-induced lesions impair the
quality of life of patients most severely. The patho-
genesis is not well characterized, but whealing is
dependent on mast cell activation, with the histology
of lesions also showing a deep dermal in¯ammatory
in®ltrate of neutrophils and eosinophils, without vas-
culitis. Treatment of delayed pressure is generally
unsatisfactory, and is often resistant to antihistamine
and a range of anti-in¯ammatory medication. Oral
steroids, although the most effective therapy, are
unsuitable for long-term use. Delayed pressure urti-
caria may persist for many years, and improved or
novel methods of management are under investiga-
tion. Journal of Investigative Dermatology Symposium
Proceedings 6:148±149, 2001
D
elayed pressure urticaria (DPU) is important because
it can interfere severely with the quality of life, the
condition may be underdiagnosed, its pathogenesis is
not de®ned, and its treatment is very dif®cult.
QUALITY OF LIFE
The severity of the impact of DPU on the quality of life has only
recently been documented in a specialist urticaria unit. When the
quality of life of patients with delayed pressure urticaria and chronic
urticaria was compared with patients with uncomplicated chronic
ordinary urticaria, using a Nottingham health pro®le, a general
health status measure, the patients with DPU were signi®cantly
more restricted in mobility and types of clothing that they could
wear, had a higher pain score, and had more problems related to
employment and hobbies (O'Donnell et al, 1997). Similar results
were obtained by using a skin disease speci®c questionnaire
(Dermatology Life Quality Index; Poon et al, 1999). In addition,
patients with DPU had the highest impairment of quality of life
compared with the other types of urticaria questioned (Poon et al,
1999). This impairment of quality of life of patients with DPU was
comparable with that seen in atopic outpatients (Poon et al, 1999).
Patients may not reveal that DPU can cause sexual dif®culties
(McFadden et al, 1998).
CLINICAL CHARACTERISTICS
DPU is characterized by the development of erythematous
swellings at sites of sustained pressure application on the skin after
a delay of 30 min to 12 h (Dover et al, 1988). The swellings are
usually pruritic and/or painful, may persist for several days, and
occasionally may blister (Mijailovic et al, 1997). Systemic features
such as ¯u-like symptoms and arthralgia may be present and on a
few occasions delayed pressure urticaria has led to obstruction of
urinary ¯ow (Poon and Kobza Black, 1998). The severity of DPU
varies in individuals with time (Lawlor et al, 1989). Nearly all (94%)
patients have associated ordinary idiopathic urticaria (Sussman et al,
1982).
The incidence of DPU was previously stated to be approximately
2% of all urticarias (Champion, 1988). It is now recognized that
DPU is more common, as 37% of patients with ordinary urticaria
attending hospital have associated DPU (Barlow, 1993). Other
types of urticaria may be associated with DPU (Dover et al, 1988),
including angiedema, symptomatic immediate, and delayed
dermographism.
DIAGNOSIS
The patient and physician may be unaware of the presence of DPU
unless direct questioning reveals the association of pressure and
development of wheals after a delay. Lesions appear at pressure sites
under tight clothes, on palms after using tools, and on soles of feet
after prolonged walking or standing.
Con®rmation of the diagnosis is made after application of a
standardized weight applied to a de®ned area of skin for a speci®ed
time results in a palpable wheal when inspected after 2±8 h (usually
6 h). The presence of wheals resulting from rods of 1.5 cm
diameter weighted with 2.5 or 3.5 kg applied for 20 min to the
skin were designated as a gold standard for DPU. Using a pen-like
instrument calibrated at 100 g per mm2 (dermographometer)
pressed for various times against the back, the best combination
of speci®city and sensitivity of the diagnosis of DPU was at 70 s
application (Barlow et al, 1993).
PATHOGENESIS
The pathogenesis of DPU is not well characterized, although a
number of potential mechanisms and mediators have been
postulated.
It has been postulated that the pressure-induced wheals may be
due to a late phase reaction (Sussman et al, 1982), but an antigen has
never been identi®ed. This reaction is dependent on mast cell
activation and reduced stainable mast cells have been demonstrated
in wheals of DPU (Barlow et al, 1995a) associated with a
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neutrophil- and eosinophil-rich in®ltrate present in some early and
late wheals (Barlow et al, 1994). There is upregulation of E selectin
(Barlow et al, 1994). These responses suggest the presence of
cytokines derived from mast or in¯ammatory cells. Increased
interleukin 6 (Lawlor et al, 1993) and TNFa and IL3 expression
related to the in¯ammatory cell in®ltrate were demonstrated in
lesions of DPU (Hermes et al, 1999).
TREATMENT
Treatment is generally unsatisfactory and there are only a few
controlled trials. Antihistamines are generally not effective
(Sussman et al, 1982; Dover et al, 1988), though high doses of
cetirizine (10 mg three times) reduced the areas of whealing in 14
patients with DPU (Kontou-Fili et al, 1991), but in clinical practice
the results have been generally disappointing.
Nonsteroidal anti-in¯ammatory drugs (NSAID) have been used
to treat DPU, with con¯icting results. Acetyl salicylic acid
(3900 mg per d in divided doses) clinical suppressed experimentally
induced wheals in six of eight patients with DPU (Sussman et al,
1982); however, in a double blind trial of indomethacin 25 mg
three times a day in 14 patients with DPU, there was no signi®cant
reduction of dermographometer-induced weal areas (Dover et al,
1988). It is important to note that NSAID may exacerbate ordinary
chronic idiopathic urticaria.
Colchicine at a dose of 0.5 mg and placebo twice a day in 13
patients with DPU in a double blind cross-over trial, did not
demonstrate a reduction of dermographometer-induced wheals
compared with placebo (Lawlor et al, 1989).
There has been an isolated case report of the usefulness of
dapsone 50 mg daily in ®ve patients (Gould et al, 1991), of
sulfasalazine up to 4 g daily in two patients (Engler et al, 1995), and
of montelukast, a leukotriene antagonist, in one patient (Berkun
and Shalit, 2000) with DPU, but larger double blind, placebo-
controlled studies are necessary to evaluate these treatments.
In a study of 44 patients with DPU, one group was randomised
to nimesulide 100 mg daily for 3 wk, ketotifen 1 mg b.d. was
added for 2 wk, and in the next 2 wk nimesulide was ceased but
ketotifen was continued. In another group prednisolone orally was
reduced from 40 mg daily for 3 wk, 30 mg daily for 2 wk, and
20 mg daily for 2 wk. There was a reduction of 93% of symptoms
in the ®rst group and 85% in the second, but longer follow-up
studies are necessary (Vena et al, 1998).
Oral steroids are the most effective treatment, but doses above
30 mg per day may be necessary, so it is unsuitable for long-term
use (Dover et al, 1988). Topical steroids under occlusion may be
helpful in pretreating small localized areas (Barlow et al, 1995b).
It is unclear whether immunotherapy including oral cyclosporine
and intravenous immunoglobulin, which have been used to treat
the most resistant autoimmune chronic urticarias, may be bene®cial
for delayed pressure urticaria.
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